Bausch Health Companies Inc. (TSX:BHC)
Canada · Delayed Price · Currency is CAD | Market Cap | 3.01B |
| Revenue (ttm) | 13.44B |
| Net Income (ttm) | 133.66M |
| Shares Out | n/a |
| EPS (ttm) | 0.36 |
| PE Ratio | 22.55 |
| Forward PE | 1.39 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 388,917 |
| Average Volume | 309,786 |
| Open | 8.02 |
| Previous Close | 8.17 |
| Day's Range | 7.77 - 8.04 |
| 52-Week Range | 5.91 - 13.74 |
| Beta | 0.41 |
| RSI | 35.77 |
| Earnings Date | Jul 30, 2025 |
About Bausch Health Companies
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products. The Intern... [Read more]
Financial Performance
In 2024, Bausch Health Companies's revenue was $9.63 billion, an increase of 9.91% compared to the previous year's $8.76 billion. Losses were -$46.00 million, -92.23% less than in 2023.
Financial numbers in USD Financial StatementsNews
Bausch Health Companies Inc. 2025 Q2 - Results - Earnings Call Presentation
Bausch Health reaffirms 2025 revenue target of $4.95B–$5.1B as debt reduction and pipeline expansion advance
Bausch Health Companies Inc. (BHC) Q2 2025 Earnings Call Transcript
Bausch Health Companies Inc. (NYSE:BHC) Q2 2025 Earnings Conference Call July 30, 2025 5:00 PM ET Company Participants Garen Sarafian - VP & Head of Investor Relations Jean-Jacques Charhon - Executiv...
Bausch Health Companies GAAP EPS of $0.40 beats by $0.36, revenue of $2.53B beats by $40M
Bausch Health Announces Second Quarter 2025 Results
Second Quarter Consolidated Revenues of $2.53 billion, up 5% on a Reported basis and 4% on an Organic (non-GAAP)1 basis over the prior year period GAAP Net Income Attributable to Bausch Health Compani...
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Bausch Health Companies Inc. (NYSE: BHC) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ: DRRX), including a novel therapeutic molecule, larsucosterol . Larsucosterol, an endogenous sulf...
Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Bausch Health Companies Inc. BHC on Tuesday agreed to indirectly acquire DURECT Corp DRRX, including a novel therapeutic molecule, larsucosterol.
Bausch Health to acquire liver drug developer Durect for $1.75 per share
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
Phase 3 data show Bausch + Lomb’s LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness The multicenter study with 380 participants confirmed t...
Bausch Health to Acquire DURECT Corporation, Strengthening Commitment to Developing Innovative Solutions for Patients with Liver Disease
DURECT's lead asset, Larsucosterol, is an epigenetic modulator with FDA Breakthrough Therapy Designation Potential to be the first FDA-approved therapeutic option for the treatment of patients with al...
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology ...
Bausch Health to redeem ~$602M of outstanding notes due 2026
Bausch Health to Reduce Debt by Approximately $900 Million Using Cash On Hand
LAVAL, QC / ACCESS Newswire / July 28, 2025 / Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC) ("Bausch Health" or the "Company") today announced that its subsidiary, Bausch Health Americas, Inc., h...
Bausch Health Announces the Appointment of Two New Members to Its Board of Directors
LAVAL, QC / ACCESS Newswire / July 24, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Michael Goettler and Sa...
CORRECTING and REPLACING: Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Nova Scotia and Two Federal Programs
This press release updates the headline of the previously posted release LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:B...
Bausch Health Appoints New Chief Accounting Officer
LAVAL, QC / ACCESS Newswire / July 10, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), a global, diversified pharmaceutical company, today announced the appointment of Steven Lee as Senior Vi...
Bausch Health, Canada Inc. Treatment for Acne Vulgaris, (Pr)CABTREO(TM) (clindamycin phosphate, adapalene and benzoyl peroxide gel), Now Available Through Public Drug Plans of Ontario, Quebec and Two Federal Programs
LAVAL, QC / ACCESS Newswire / July 9, 2025 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), today announced that PrCABTREOTM (clindamycin phosphate, adapalene an...
Bausch Health's Gastroenterology Business, Salix Pharmaceuticals, Launches Fresh "I Wish I Knew" Campaign to Educate People About Xifaxan(R) (rifaximin) for Adults at Risk of Overt Hepatic Encephalopathy Recurrence
Focused on highlighting real patient experiences, Salix continues to lead the charge in educating and advocating for the hepatic encephalopathy community LAVAL, QC / ACCESS Newswire / July 7, 2025 / B...
Bausch Health to Announce Second Quarter 2025 Results on July 30
LAVAL, QC / ACCESS Newswire / July 2, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release second quarter 2025 financial results after market close on Wednesday, July 30, 2025. Bausch ...
Marriott Vacations, Bausch Health See Activist Actions
Bausch + Lomb Announces Closing of Upsized €675 Million Senior Secured Notes Offering and Partial Credit Agreement Refinancing, Including Upsized $2.325 Billion Term Loan Facility
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO) (“Bausch + Lomb” or the “company”), a leading global eye health company dedicated to helping people see better to live bet...
A Billionaire Trump Supporter Is Buying These Two Stocks
John Paulson, former hedge-fund manager, bought large blocks of Bausch Health and Perpetua Resources through funds.
Bausch Health Shares Rise as Nonexecutive Chairperson Paulson Buys $21.2M in Shares
Bausch Health shares rose Wednesday morning after a director made a substantial purchase of company stocks.
Repricing Potential Driven By Deleveraging
Bausch Health is significantly undervalued, trading at depressed multiples due to high debt and patent risk, but its core business remains stable and cash generative. Recent refinancing has extended d...